Autres langues GSK plc

Actions

GSK

GB00BN7SWP63

Produits pharmaceutiques

Marché Fermé - London S.E. 17:35:00 24/08/2026			Varia. 5j.	Varia. 1 janv.
1 890,50 ^GBX	-1,46%		+2,11%	+3,62%

24/08	Le FTSE 100 surperforme alors que les cours du pétrole reculent	AN
24/08	Les bourses européennes clôturent majoritairement en baisse lundi ; le secrétaire au Trésor américain Scott Bessent va détailler les sanctions contre l'Iran	MT

Autres langues

24/08	FTSE 100 outperforms as oil price heads lower
24/08	European Stocks Close Mostly Lower in Monday Trading; US Treasury Secretary Scott Bessent to Give Details on Iran Sanctions
24/08	UK's FTSE 100 Rises as US-Iran Conflict Escalates; GSK Declines
24/08	GSK US President sells shares worth USD2.3 million
24/08	Global markets live: Nvidia, Eli Lilly, ExxonMobil, GSK…
24/08	Exchange-Traded Funds, Equity Futures Fall Pre-Bell Monday as Investors Await Details on US Sanctions Against Iran
24/08	GSK plc Announces Jemperli Accepts for Priority Review by US FDA for dMMR/MSI-H Locally Advanced Rectal Cancer
24/08	Gsk plc Announces Approval of Hibsago (Bepirovirsen) in Japan as First Functional Cure for Chronic Hepatitis B
24/08	GSK Obtains First Global Approval for Chronic Hepatitis B Drug Hibsago
24/08	GSK gets hepatitis approval in Japan, fast US review in rectal cancer
24/08	GSK Says Chronic Hepatitis B Treatment Approved in Japan
24/08	GSK Says Jemperli Accepted for Priority Review as Potential Treatment for Rectal Cancer
24/08	GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy
24/08	GSK drug approved in Japan; Tracsis trading in-line
24/08	FDA prüft Darmkrebsmedikament Jemperli von GSK vorrangig
24/08	GSK's Rectal Cancer Drug Jemperli Accepted for Priority Review by FDA
24/08	GSK's Hibsago Wins Japanese Approval for Chronic Hepatitis B Treatment
24/08	US FDA Accepts GSK's Supplemental Application for Rectal Cancer Drug for Priority Review
24/08	GSK : Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B
24/08	GSK : Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer
21/08	WINNERS & LOSERS: Hunting falls on outlook cut; miners rise
20/08	Pharma sector doubles down on AI amid hopes of slashing costs, timelines
20/08	Cancer vaccines finally garner the spotlight
18/08	Chugai grants GSK exclusive global license for AID351 dengue antibody
17/08	FTSE 100 drifts lower as oil price pushes higher